Abstract
The results of the global BOLERO-2 trial established the efficacy and safety of combination everolimus (EVE, an mTOR inhibitor) and exemestane (EXE) in the treatment of ER+, HER2-, locally advanced, recurrent, or metastatic breast cancer (ABC). BOLERO-5 investigated this combination in Chinese post-menopausal women with ER+, HER2- ABC, refractory to letrozole or anastrozole (NCT03312738).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have